OCT 16, 2013 2:00 PM PDT

Novel therapies for ALK mutated cancers

C.E. Credits: CE
Speaker

Abstract

Non Small Cell Lung Cancer (NSCLC) is one of the most significant causes of cancer-related mortality worldwide. In about 6-7% of NSCLC, rearrangements involving the Anaplastic Lymphoma Kinase (ALK) play a strong driver role in tumor progression. Indeed, blocking ALKs kinase activity with the use of selective kinase inhibitors, such as crizotinib, induces an exceptionally high rate of clinical responses in ALK-rearranged NSCLC. Unfortunately, almost all patients relapse due to resistance to crizotinib developed in tumors by various molecular mechanisms. Therefore, developing additional therapeutic options for ALK-rearranged NSCLC is a pressing clinical need. The ALK protein has many, quite unique, features of an ideal tumor onco-antigen: it is specifically expressed by tumor cells with very low and limited expression in normal tissues, it is naturally immunogenic in humans, as indicated by studies on patients with ALK-rearranged tumors, and it is required for tumor survival and growth, which greatly decreases the chances of ALK negative clones to escape the immune system. In preclinical experiments in mouse models of ALK-driven cancers, we demonstrated that DNA-based ALK vaccine elicited a specific and powerful immune response against the ALK protein that was sufficient to strongly reduce the growth of ALK-rearranged lymphoma and lung carcinoma. Based on this data, we predict that a highly potent and safe ALK-targeted vaccine will be beneficial for the treatment of lung cancer and lymphoma patients. In principle, this vaccine could be extended to any ALK-expressing cancer.


Show Resources
You May Also Like
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
APR 01, 2021 8:00 AM PDT
C.E. CREDITS
APR 01, 2021 8:00 AM PDT
Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
FEB 24, 2021 10:00 AM PST
C.E. CREDITS
FEB 24, 2021 10:00 AM PST
DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
MAR 18, 2021 8:00 AM PDT
C.E. CREDITS
MAR 18, 2021 8:00 AM PDT
DATE: March 18, 2021 TIME: 8:00am PDT Sequencing of bulk cells, single cells, and nuclei is opening doors in the understanding of complex biological processes....
MAR 16, 2021 10:00 AM PDT
C.E. CREDITS
MAR 16, 2021 10:00 AM PDT
Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
OCT 16, 2013 2:00 PM PDT

Novel therapies for ALK mutated cancers

C.E. Credits: CE

Specialty

Next-Generation Sequencing

Research

Clinical Genetic Molecular Biologist Scientist (Cgmbs)

Health

Research And Development

Earth Science

University

Geography

Asia100%

Registration Source

Website Visitors100%

Job Title

Medical Laboratory Technician100%

Organization

Distribution/sales50%

Manufacturer - Other50%


Show Resources
Loading Comments...
Show Resources